Related Experiment Video
Updated: Mar 1, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and
Vincent Wing Sun Liu1, Wing Lung Yau2, Chun Wai Tam3
1School of Biomedical Sciences, The University of Hong Kong, Hong Kong, China. vwsliu@hku.hk.
Abstract:
A major current challenge in the treatment of advanced prostate cancer, which can be initially controlled by medical or surgical castration, is the development of effective, safe, and affordable therapies against progression of the disease to the stage of castration resistance. Here, we showed that in LNCaP and 22Rv1 prostate cancer cells transiently overexpressing androgen receptor splice variant-7 (AR-V7), nuclear factor-kappa B (NF-κB) was activated and could result in up-regulated interleukin (IL)-6 gene expression, indicating a positive interaction between AR-V7 expression and activated NF-κB/IL-6 signaling in castration-resistant prostate cancer (CRPC) pathogenesis. Importantly, both AR-V7-induced NF-κB activation and IL-6 gene transcription in LNCaP and 22Rv1 cells could be inhibited by melatonin. Furthermore, stimulation of AR-V7 mRNA expression in LNCaP cells by betulinic acid, a pharmacological NF-κB activator, was reduced by melatonin treatment. Our data support the presence of bi-directional positive interactions between AR-V7 expression and NF-κB activation in CRPC pathogenesis. Of note, melatonin, by inhibiting NF-κB activation via the previously-reported MT₁ receptor-mediated antiproliferative pathway, can disrupt these bi-directional positive interactions between AR-V7 and NF-κB and thereby delay the development of castration resistance in advanced prostate cancer. Apparently, this therapeutic potential of melatonin in advanced prostate cancer/CRPC management is worth translation in the clinic via combined androgen depletion and melatonin repletion.
Insights
Melatonin inhibits the interaction between androgen receptor variant-7 (AR-V7) and nuclear factor-kappa B (NF-κB) signaling. This disruption delays castration resistance in advanced prostate cancer, offering a potential new therapy.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Advanced prostate cancer often progresses to castration resistance despite initial treatment.
- Androgen receptor splice variant-7 (AR-V7) and nuclear factor-kappa B (NF-κB) signaling are implicated in castration-resistant prostate cancer (CRPC) pathogenesis.
- Interleukin-6 (IL-6) is a key mediator in CRPC progression.
Purpose of the Study:
- To investigate the interaction between AR-V7 and NF-κB/IL-6 signaling in prostate cancer cells.
- To evaluate the effect of melatonin on AR-V7-induced NF-κB activation and IL-6 expression.
- To explore the therapeutic potential of melatonin in delaying castration resistance.
Main Methods:
- Utilized LNCaP and 22Rv1 prostate cancer cell lines.
- Overexpressed AR-V7 in cell lines.
- Assessed NF-κB activation and IL-6 gene expression.
- Treated cells with melatonin and betulinic acid (NF-κB activator).
Main Results:
- AR-V7 overexpression activated NF-κB and up-regulated IL-6 expression.
- Melatonin inhibited AR-V7-induced NF-κB activation and IL-6 transcription.
- Melatonin reduced AR-V7 mRNA expression stimulated by betulinic acid.
- Demonstrated bi-directional positive interactions between AR-V7 and NF-κB.
Conclusions:
- Melatonin disrupts the positive feedback loop between AR-V7 and NF-κB signaling.
- Melatonin inhibits NF-κB activation via the MT₁ receptor pathway.
- Melatonin holds therapeutic potential for advanced prostate cancer and CRPC management.
- Combined androgen depletion and melatonin repletion may be a viable clinical strategy.
Related Concept Videos
RNA Splicing
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors
Regulation of Nuclear Protein Sorting
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

